Bone turnover in hyperthyroidism before and after thyrostatic management.
Hyperthyroidism is associated with enhanced osteoblastic and osteoclastic activity, and patients frequently have low bone mineral density and high bone turnover. The aim of this study was to examine the bone formation and resorption markers trend in 12 female patients, before and after normalization of thyroid activity. The following measurements were made at baseline and 1 and 6 months after hormone normalization induced by methimazole treatment: total alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), collagen type C-terminal propeptide (PICP), osteocalcin (BGP), telopeptide (ICTP), urinary-hydroxyproline/urinary creatinine (uOHP/uCreat), urinary calcium/urinary creatinine (uCa/uCreat) and deoxypyridinoline crosslinks (D-Pyr). Compared with controls, all of these parameters were significantly increased (ALP p = 0.014; BALP p = 0.0001; PICP p = 0.013; BGP p = 0.009; ICTP p = 0.0001; uOHP/uCreat p = 0.002; uCa/uCreat p = 0.044; crosslinks p = 0.0001). After treatment the values of ALP, BALP and PICP in hyperthyroid patients showed an initial slight increase and then a significant downwards trend (ALP p = 0.008, BAP p = 0.001, PICP p = 0.026). Furthermore, resorption markers showed a significant decrease (uOHP/ uCreat p < 0.005 and D-Pyr p < 0.008). As regards lumbar BMD patients, measurements were significantly reduced in comparison with the control group (p = 0.005). Six months after serum thyroid hormones level normalization, we observed a significant increase (p=0.014 vs baseline). Both neoformation and resorption markers are useful to assess pathological bone turnover and bone involvement in hyperthyroidism. They could also be employed to monitor the effect of antithyroid treatment on bone and to indicate if bone antiresorption therapy should be considered.
Isaia
G C
GC
Department of Internal Medicine, University of Turin, Italy.
Roggia
C
C
Gola
D
D
Stefano
M D
MD
Gallone
G
G
Aimo
G
G
Ardissone
P
P
Mussetta
M
M
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D013956:Antithyroid Agents / Q000627:therapeutic use*; D015519:Bone Density; D016723:Bone Remodeling; D001842:Bone and Bones / Q000201:enzymology; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000503:physiopathology*; D007527:Isoenzymes / Q000097:blood; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood; D011347:Procollagen / Q000097:blood
D000596:Amino Acids; D013956:Antithyroid Agents; D024042:Collagen Type I; D007527:Isoenzymes; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; D008713:Methimazole; C036020:deoxypyridinoline; D003094:Collagen; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline